179 related articles for article (PubMed ID: 35981569)
1. Sorafenib combined with STAT3 knockdown triggers ER stress-induced HCC apoptosis and cGAS-STING-mediated anti-tumor immunity.
Wang X; Hu R; Song Z; Zhao H; Pan Z; Feng Y; Yu Y; Han Q; Zhang J
Cancer Lett; 2022 Oct; 547():215880. PubMed ID: 35981569
[TBL] [Abstract][Full Text] [Related]
2. Hyperbaric oxygen facilitates teniposide-induced cGAS-STING activation to enhance the antitumor efficacy of PD-1 antibody in HCC.
Li K; Gong Y; Qiu D; Tang H; Zhang J; Yuan Z; Huang Y; Qin Y; Ye L; Yang Y
J Immunother Cancer; 2022 Aug; 10(8):. PubMed ID: 36002188
[TBL] [Abstract][Full Text] [Related]
3. IL-22 signaling promotes sorafenib resistance in hepatocellular carcinoma via STAT3/CD155 signaling axis.
Chen J; Sun S; Li H; Cai X; Wan C
Front Immunol; 2024; 15():1373321. PubMed ID: 38596684
[TBL] [Abstract][Full Text] [Related]
4. SC-2001 overcomes STAT3-mediated sorafenib resistance through RFX-1/SHP-1 activation in hepatocellular carcinoma.
Su JC; Tseng PH; Wu SH; Hsu CY; Tai WT; Li YS; Chen IT; Liu CY; Chen KF; Shiau CW
Neoplasia; 2014 Jul; 16(7):595-605. PubMed ID: 25047655
[TBL] [Abstract][Full Text] [Related]
5. DNMT3b/OCT4 expression confers sorafenib resistance and poor prognosis of hepatocellular carcinoma through IL-6/STAT3 regulation.
Lai SC; Su YT; Chi CC; Kuo YC; Lee KF; Wu YC; Lan PC; Yang MH; Chang TS; Huang YH
J Exp Clin Cancer Res; 2019 Nov; 38(1):474. PubMed ID: 31771617
[TBL] [Abstract][Full Text] [Related]
6. Sorafenib and its derivative SC-49 sensitize hepatocellular carcinoma cells to CS-1008, a humanized anti-TNFRSF10B (DR5) antibody.
Chen KF; Chen HL; Shiau CW; Liu CY; Chu PY; Tai WT; Ichikawa K; Chen PJ; Cheng AL
Br J Pharmacol; 2013 Feb; 168(3):658-72. PubMed ID: 22978563
[TBL] [Abstract][Full Text] [Related]
7. Chemical and genetic inhibition of STAT3 sensitizes hepatocellular carcinoma cells to sorafenib induced cell death.
Xie L; Zeng Y; Dai Z; He W; Ke H; Lin Q; Chen Y; Bu J; Lin D; Zheng M
Int J Biol Sci; 2018; 14(5):577-585. PubMed ID: 29805309
[TBL] [Abstract][Full Text] [Related]
8. Melatonin Increases the Sensitivity of Hepatocellular Carcinoma to Sorafenib through the PERK-ATF4-Beclin1 Pathway.
Zhou B; Lu Q; Liu J; Fan L; Wang Y; Wei W; Wang H; Sun G
Int J Biol Sci; 2019; 15(9):1905-1920. PubMed ID: 31523192
[TBL] [Abstract][Full Text] [Related]
9. Inflammatory microenvironment of fibrotic liver promotes hepatocellular carcinoma growth, metastasis and sorafenib resistance through STAT3 activation.
Jiang Y; Chen P; Hu K; Dai G; Li J; Zheng D; Yuan H; He L; Xie P; Tu M; Peng S; Qu C; Lin W; Chung RT; Hong J
J Cell Mol Med; 2021 Feb; 25(3):1568-1582. PubMed ID: 33410581
[TBL] [Abstract][Full Text] [Related]
10. Sorafenib suppresses radioresistance and synergizes radiotherapy-mediated CD8
Cheng CC; Ho AS; Peng CL; Chang J; Sie ZL; Wang CL; Chen YL; Chen CY
Int Immunopharmacol; 2022 Nov; 112():109110. PubMed ID: 36037651
[TBL] [Abstract][Full Text] [Related]
11. Lenvatinib Synergistically Promotes Radiation Therapy in Hepatocellular Carcinoma by Inhibiting Src/STAT3/NF-κB-Mediated Epithelial-Mesenchymal Transition and Metastasis.
Weng YS; Chiang IT; Tsai JJ; Liu YC; Hsu FT
Int J Radiat Oncol Biol Phys; 2023 Mar; 115(3):719-732. PubMed ID: 36245124
[TBL] [Abstract][Full Text] [Related]
12. ATP citrate lyase inhibitor triggers endoplasmic reticulum stress to induce hepatocellular carcinoma cell apoptosis via p-eIF2α/ATF4/CHOP axis.
Zheng Y; Zhou Q; Zhao C; Li J; Yu Z; Zhu Q
J Cell Mol Med; 2021 Feb; 25(3):1468-1479. PubMed ID: 33393219
[TBL] [Abstract][Full Text] [Related]
13. Targeting the PD-L1/DNMT1 axis in acquired resistance to sorafenib in human hepatocellular carcinoma.
Liu J; Liu Y; Meng L; Liu K; Ji B
Oncol Rep; 2017 Aug; 38(2):899-907. PubMed ID: 28627705
[TBL] [Abstract][Full Text] [Related]
14. Dovitinib induces apoptosis and overcomes sorafenib resistance in hepatocellular carcinoma through SHP-1-mediated inhibition of STAT3.
Tai WT; Cheng AL; Shiau CW; Liu CY; Ko CH; Lin MW; Chen PJ; Chen KF
Mol Cancer Ther; 2012 Feb; 11(2):452-63. PubMed ID: 22180308
[TBL] [Abstract][Full Text] [Related]
15. Blocking CD47 promotes antitumour immunity through CD103
Wang S; Wu Q; Chen T; Su R; Pan C; Qian J; Huang H; Yin S; Xie H; Zhou L; Zheng S
J Hepatol; 2022 Aug; 77(2):467-478. PubMed ID: 35367532
[TBL] [Abstract][Full Text] [Related]
16. DDX24 regulates the chemosensitivity of hepatocellular carcinoma to sorafenib via mediating the expression of SNORA18.
Gan H; Li L; Hu X; Cai J; Hu X; Zhang H; Zhao N; Xu X; Guo H; Pang P
Cancer Biol Ther; 2022 Dec; 23(1):1-14. PubMed ID: 36310384
[TBL] [Abstract][Full Text] [Related]
17. KCNQ1OT1 contributes to sorafenib resistance and programmed death‑ligand‑1‑mediated immune escape via sponging miR‑506 in hepatocellular carcinoma cells.
Zhang J; Zhao X; Ma X; Yuan Z; Hu M
Int J Mol Med; 2020 Nov; 46(5):1794-1804. PubMed ID: 33000204
[TBL] [Abstract][Full Text] [Related]
18. Sorafenib and CuB exert synergistic antitumor effects against hepatocellular carcinoma cells via inhibition of STAT3 phosphorylation.
Wang X; Li H; Li D; Bai Y; Zhang Y; Yan X; Li J; Zhao R; Liu J; Liu W; Shi M; Xu C; Yang T; Zhang T
FEBS Open Bio; 2021 Jan; 11(1):133-145. PubMed ID: 33176070
[TBL] [Abstract][Full Text] [Related]
19. Downregulation of protein disulfide‑isomerase A3 expression inhibits cell proliferation and induces apoptosis through STAT3 signaling in hepatocellular carcinoma.
Kondo R; Ishino K; Wada R; Takata H; Peng WX; Kudo M; Kure S; Kaneya Y; Taniai N; Yoshida H; Naito Z
Int J Oncol; 2019 Apr; 54(4):1409-1421. PubMed ID: 30720090
[TBL] [Abstract][Full Text] [Related]
20. RECQL4 Inhibits Radiation-Induced Tumor Immune Awakening via Suppressing the cGAS-STING Pathway in Hepatocellular Carcinoma.
Hong W; Zhang Y; Wang S; Li Z; Zheng D; Hsu S; Zhou J; Fan J; Chen Z; Xia X; Zeng Z; Gao Q; Yu M; Du S
Adv Sci (Weinh); 2024 Apr; 11(16):e2308009. PubMed ID: 38381090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
